Shareholders to Vote on Massive Dilution, Dual Reverse Stock Splits to Avoid Delisting

summarizeSummary

Jaguar Health is seeking shareholder approval for a massive increase in authorized shares, two highly aggressive reverse stock splits, and significant debt-to-equity conversion, all aimed at addressing Nasdaq delisting and critical capital requirements.

check_boxKey Events

• Proposed Increase in Authorized Shares

  Shareholders will vote on increasing authorized common stock from 298,000,000 to 500,000,000 shares. This increase of 202,000,000 shares represents a potential dilution of over 1600% relative to the 12,419,277 shares currently outstanding, intended for capital raising, debt restructuring, and Series O Preferred Stock conversion.

• Two Aggressive Reverse Stock Splits Proposed

  The company proposes two separate reverse stock splits, each with a ratio between 1-for-15 and 1-for-150. If both are approved and effected, the aggregate ratio could be up to 1-for-22,500, a measure to regain compliance with Nasdaq's minimum bid price requirement following a delisting notice on March 6, 2026.

• Approval for $7.06M Debt-to-Equity Conversion

  Shareholders are asked to approve the issuance of common stock to exchange a secured promissory note with Streeterville Capital, LLC, with an outstanding balance of approximately $7,057,500. This conversion could result in the issuance of over 70 million shares at a hypothetical $0.10 exchange price, leading to over 500% dilution for current shareholders.

• Special Meeting Scheduled

  A Special Meeting of Stockholders is scheduled for April 20, 2026, to vote on these critical proposals, which are presented as necessary to fund operations and avoid defaulting on debt covenants.

auto_awesomeAnalysis

This preliminary proxy statement reveals Jaguar Health's dire situation, proposing multiple extreme measures to address Nasdaq delisting threats and critical capital needs. The company is seeking shareholder approval for two separate reverse stock splits, each with a ratio of up to 1-for-150, potentially resulting in an aggregate reverse split of up to 1-for-22,500. This unprecedented level of reverse splitting underscores the severe risk of delisting, following the Nasdaq notice received on March 6, 2026. Concurrently, the company seeks to increase authorized common shares by 202 million, a move that could lead to over 1600% dilution relative to current outstanding shares. Furthermore, shareholders will vote on approving the issuance of shares to convert a $7.06 million secured promissory note, which could result in over 500% dilution based on hypothetical low exchange prices. These proposals collectively signal significant financial distress and a desperate need for capital, with substantial dilution for existing shareholders.